Company Overview of G&H Brands LLC
G&H Brands LLC provides on-demand treatment for premature ejaculation. It offers Promescent, a metered topical anesthetic spray containing Lidocaine as its active ingredient to control premature ejaculation. The company was founded in 2008 and is headquartered in Calabasas, California.
24992 Normans Way
Calabasas, CA 91302
Founded in 2008
Key Executives for G&H Brands LLC
Compensation as of Fiscal Year 2014.
G&H Brands LLC Key Developments
Absorption Pharmaceuticals LLC Collaborates with Kaiser Permanente Announces Initiation of Clinical Trial to Evaluate the Efficacy of Promescent Lidocaine Spray for Men with Premature Ejaculation
Dec 11 13
Absorption Pharmaceuticals LLC in collaboration with Kaiser Permanente announced the initiation of a clinical trial to evaluate the efficacy of Promescent lidocaine spray for men with premature ejaculation (PE). This Phase III, double blind, placebo-controlled, randomized study will measure the intravaginal ejaculatory latency time (IELT) for subjects aged 18 and older. The study protocol will adhere to International Society of Sexual Medicine's (ISSM) definition of PE and guidelines by the Standards for Clinical Trials in Male Sexual Dysfunction Committee. The Promescent(R) trial will be conducted at two Kaiser Permanente Southern California medical centers: Los Angeles and San Diego. Over the course of a year, the study will screen approximately 150 subjects with an estimated 20% screen failure rate to produce a total of 120 subjects. Subjects who provide written informed consent, meet all eligibility criteria and are enrolled to the study will be randomized to one of two arms: active treatment (Promescent lidocaine spray) or placebo. Each arm will contain 60 subjects stratified by site. Premature Ejaculation (PE) continues to be a leading cause of sexual dysfunction among men of all ages, leading to a significant decrease in self-esteem and healthful relationships. Currently, 200 pharmacies and over 1,000 urologists throughout America recommend Promescent's patented, one-of-a-kind formula to aid their patients.
Absorption Pharmaceuticals to Receive Patent for Premature Ejaculation Topical Medication
Apr 29 13
Absorption Pharmaceuticals announced that the U.S. Patent and Trademark Office has indicated that it will grant a patent related to the use of its topical medication, Promescent, for premature ejaculation (PE). The patent protects novel lidocaine-only eutectic formulation which enables maximum absorption of the anesthetic through the skin's outer layer and provides men with improved ejaculatory control while maintaining great sensory feeling. Available over-the-counter under FDA Monograph 21 CFR 348.10, Promescent is gaining acceptance by urologists and general practitioners across the U.S. The award of this patent strengthens Absorption Pharmaceuticals position as a leader in the treatment of premature ejaculation.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries